Back to top
more

Sangamo Therapeutics (SGMO)

(Delayed Data from NSDQ)

$2.81 USD

2.81
15,356,891

+0.34 (13.77%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $2.82 +0.01 (0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of 23.53% and 4.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Gets Approval for New Eczema Drug in Europe

by Zacks Equity Research

Pfizer's (PFE) oral JAK inhibitor, Cibinqo, gets approval for treating atopic dermatitis in adults who are candidates for systemic therapy in Europe.

Wall Street Analysts Think Sangamo (SGMO) Could Surge 64%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Sangamo (SGMO) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of 2.94% and 5.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Sangamo Therapeutics (SGMO) Q3 Earnings Expected to Decline

by Zacks Equity Research

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval

by Zacks Equity Research

Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -10.00% and -6.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Sangamo Therapeutics (SGMO) Q2 Earnings Expected to Decline

by Zacks Equity Research

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

by Zacks Equity Research

The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) new MAA in EU includes 52 weeks' data from the phase III GENEr8-1 study, along with four and three-year follow-up data from the ongoing phase I/II dose escalation study.

Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal

by Zacks Equity Research

Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.

BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review

by Zacks Equity Research

The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.

Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study

by Zacks Equity Research

Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.

Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate

by Zacks Equity Research

Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)

Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders

by Zacks Equity Research

Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -10.34% and -17.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag

by Zacks Equity Research

FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.

Stock Market News for Feb 26, 2021

by Zacks Equity Research

U.S. stock markets closed sharply lower on Thursday as rising bond yields raised concerns among market participants on risky assets like equities

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -61.11% and -31.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy

by Zacks Equity Research

BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.

Sangamo Therapeutics (SGMO) Catches Eye: Stock Jumps 6.5%

by Zacks Equity Research

Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.

Kevin Cook headshot

CRISPR Gene Editing: Owning the Future of Medicine

by Kevin Cook

In the Century of Biology, it pays to own the future of curing disease at the root.

Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate

by Zacks Equity Research

Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.

Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of 95.83% and 101.79%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?